Company Overview - Arcus Biosciences is an oncology biotech company with a focus on developing combination therapies that complement certain disease pathways [1] - The company's intellectual property (IP) has the potential to enhance treatment outcomes when used in combination with other drugs [1] Analyst Background - The author, Myriam Hernandez Alvarez, holds a Ph D in computer applications from the University of Alicante, Spain, and has professional collaborations with Edgar Torres H [1] - The author's analyses are conducted independently and adhere to Seeking Alpha's Shared Association Guidelines [1] Disclosure Information - The author has no stock, option, or derivative positions in any of the mentioned companies and no plans to initiate such positions within the next 72 hours [2] - The article expresses the author's own opinions and is not influenced by any compensation or business relationships with the mentioned companies [2]

I covered Arcus Biosciences (NYSE: RCUS ) back in August 2023, and I said that the company had Terry Rosen, well-known biotech entrepreneur, as its CEO, major collaborations, a huge load of cash, but little data to justify all that. Since then, the company hasAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive ...

COMBINING TO CURE ® Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. CORPORATE PRESENTATION Nov. 6, 2024 Forward-looking Statements/Safe Harbor 2 Forward Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements reg ...

Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Pia Eaves - Vice President-Investor Relations and Strategy Terry Rosen - Chief Executive Officer Jennifer Jarrett - Chief Operating Officer Bob Goeltz - Chief Financial Officer Dimitry Nuyten - Chief Medical Officer Juan Jaen - President Conference Call Participants Yigal Nochomovitz - Citi Jonathan Miller - Evercore ISI Peter Lawson - Barclays Asthika Goonewardene - Truist Daina Graybosch - ...

Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.54%. A quarter ago, it was expected that this company would post a loss of $1.02 per share when it actually produced a loss of $1.02, delivering no surprise.Over the last four quarters, the company has surpassed con ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________ FORM 10-Q _____________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to _______________ | --- | --- | |--------------------------------- ...

Exhibit 99.1 Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update • Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50 mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a p ...

Arcus Biosciences, Inc. (NYSE: RCUS ) develops immunotherapies for lung, gastrointestinal (GI), kidney, pancreatic, and colorectal cancers. The company discovers and designs small molecules and antibodies optimized for combination therapies. Then, it aims for accelerated development through a deep understanding of cancer mechanisms and strategic collaborations with My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, ...

Matteo Colombo/DigitalVision via Getty Images Topline Summary and Update Arcus Biosciences, Inc. (NYSE:RCUS) is a cancer-focused biotech I've covered a few times with relative optimism, and as an investment thesis, it has yet to pay off. However, with an important trial update at this year's ASCO Annual Meeting and a number of important upcoming catalysts, I'm inclined to remain upbeat about the company's outlook, despite the more recent setbacks faced by the TIGIT story. Let's take another look. Pipeline U ...

Arcus Biosciences, Inc. (NYSE:RCUS) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Pia Eaves – Vice President-Investor Relations and Strategy Terry Rosen – Chief Executive Officer Jennifer Jarrett – Chief Operating Officer Bob Goeltz – Chief Financial Officer Dimitry Nuyten – Chief Medical Officer Conference Call Participants Yigal Nochomovitz – Citi Jonathan Miller – Evercore Daina Graybosch – Leerink Partners Asthika Goonewardene – Truist Securities Operator Good afternoon ...